Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses optimal neoadjuvant and adjuvant therapy for patients with early-stage triple-negative breast cancer (TNBC), including the optimal chemotherapy backbone, the role of PARP inhibitors in patients with BRCA1/2 mutations, as well as KEYNOTE-522 (NCT03036488) that showed a significant improvement in pathological complete response (pCR), event-free and distant recurrence-free survival with pembrolizumab. Prof. Rugo also highlights areas of unmet need, including what to do when patients do not achieve a pCR, education surrounding immune toxicity, as well as ongoing studies aiming to personalize immunotherapy in patients with TNBC. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.